DOB Equity

PE AI focus Amsterdam, Netherlands · Founded 1997

A Dutch family-backed impact investor focused on East Africa, actively co-investing in scalable, socially beneficial healthtech and agritech companies (e.g., Ilara Health).

About DOB Equity

DOB Equity is a Dutch family-backed impact investor with an East Africa specialization that gives it a distinct profile in the African healthtech ecosystem. The firm makes Series A and Series B investments in the $1M to $5M range, focused on scalable, socially beneficial businesses across healthcare, agritech, and adjacent sectors in Kenya, Uganda, Tanzania, Rwanda, and Ethiopia. DOB has been a credible co-investor alongside specialist Africa funds like TLcom and Novastar, and its participation in companies like Ilara Health, the Kenyan diagnostics-for-clinics platform, signals the kind of opportunities it gravitates toward: tech-enabled health services that reach underserved populations at scale and have measurable health outcomes alongside venture-grade returns. The firm sits in a sweet spot for founders who want patient capital but resist the heavier covenants of pure development-finance institutions. The right founder profile is a team building infrastructure, diagnostics, or care delivery models that materially expand access in East African markets, with revenue traction or strong evidence that the unit economics work outside grant-funded pilots. The wrong fit is a founder targeting purely commercial Western markets or a pure software play with no African distribution thesis. The right entry path is through warm introductions from co-investors like TLcom Capital, Novastar Ventures, AAIC, or the Mastercard Foundation network, or through the Dutch development-finance ecosystem including FMO and DGGF. Cold inbound to the Amsterdam office is feasible but slower. When pitching, lead with both the health-impact metric and the venture-quality financial trajectory; DOB will not accept a story that sacrifices one for the other, and they have seen enough impact-washing to be skeptical of soft numbers. AI is welcome where it materially improves diagnostic accuracy, clinical decision support, or operational efficiency, but the firm is fundamentally an outcomes investor rather than a technology fetishist. Caveats: DOB is a smaller, family-office-anchored vehicle, so founders should not expect a multi-stage check-writer who follows on through Series C. The firm is also more conservative on governance and ESG than a typical Silicon Valley fund, which is a feature rather than a bug for founders who appreciate that institutional discipline, but a friction point for founders who want a passive co-investor. Use DOB as a values-aligned, locally credible partner that strengthens your East African positioning with downstream development-finance and impact-aligned capital.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.
Portfolio data coming soon. Know their portfolio? Suggest an edit →
Team information coming soon. Know the partners? Suggest an edit →

Pitch / review this investor

Have you raised from DOB Equity? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.